Introduction
============

The aim of the study was to evaluate the clinical impact of polymyxin-B hemoperfusion (HP-PMX) as adjuvant therapy versus conventional treatment in septic shock (SS) patients with high endotoxemia.

Methods
=======

A retrospective analysis of the clinical profile and evolution related to the treatment strategy of SS patients with a high endotoxin activity (EA) level (\>0.6 units) attending our ICU from January to August 2007. All patients (*n*= 16) were treated with standard therapy (ST) according to the Surviving Sepsis Campaign. According to our ICU practice, adjuvant therapy with HP-PMX (twice, 2 hours/session with an interval of 24 hours) was performed only in SS patients with known or presumed Gram-negative and Gram-positive infections, worsening of haemodynamic instability in the next 6 hours of diagnosis and ≥ 3 organ failures (PMX group, *n*= 8). The clinical profile was evaluated in the two groups (ST vs PMX group) at T0 (SS diagnosis, start of HP-PMX) and at T1 (at 48 hours). The Student *t*test for paired values was used for statistical purpose (*P*\< 0.05 significant).

Results
=======

At T0, the clinical profile of the two groups of high EA level SS patients was similar (EA level, age, SOFA score, mean arterial pressure, norepinephrine, lactates, PaO~2~/FiO~2~, continuous renal replacement therapy, used of activated protein C). Otherwise the PMX group showed a significant improvement of clinical conditions compared with the ST group at T1 (Table [1](#T1){ref-type="table"}). The ICU length of stay was significantly longer in the PMX group versus the ST group (21.5 ± 21.3 vs 53.6 ± 67 days, *P*\< 0.05). Further PMX-HP resulted in a reduction of ICU mortality when compared with ST in high EA level SS patients, probably due to endotoxin removal (45% vs 16%, not significant due to small sample size).

###### 

Evolution of high endotoxin activity level in septic shock patients

                              T0      T1      *P*value
  --------------------------- ------- ------- -----------------
  Norepinephrine, ST group    0.58    0.33    Not significant
  Norepinephrine, PMX group   0.85    0.28    \<0.05
  SOFA score, ST group        11.5    11.1    Not significant
  SOFA score, PMX group       14.15   12.17   \<0.05
  Lactate, ST group           5.41    4.71    Not significant
  Lactate, PMX group          7.94    5.35    \<0.05

Conclusion
==========

We can question whether the EA level could be a useful guide to early institution of specific anti-lipopolysaccharide treatments.
